Nakakita Yakuhin Co., Ltd.
Nakakita Yakuhin Co., Ltd., a prominent player in the drugs and druggists' sundries merchant wholesalers industry, is headquartered in Japan. Established in 1948, the company has built a strong reputation for its commitment to quality and service in the pharmaceutical sector. With a focus on wholesaling a diverse range of pharmaceutical products, Nakakita Yakuhin stands out for its extensive network and reliable supply chain management.
Operating primarily in Japan, the company has expanded its reach to various regions, ensuring that healthcare providers have access to essential medications and sundries. Nakakita Yakuhin's core offerings include prescription drugs, over-the-counter medications, and health-related products, all distinguished by their adherence to stringent quality standards. The company’s dedication to innovation and customer satisfaction has solidified its position as a trusted partner in the healthcare industry.
-3 vs industry average
Nakakita Yakuhin Co., Ltd.’s score of 18 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Nakakita Yakuhin Co., Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Drugs and Druggists' Sundries Merchant Wholesalers has below-average carbon intensity
Industry performance
The Drugs and Druggists' Sundries Merchant Wholesalers industry has reduced its overall emissions by 35% since 2018
Reported emissions
No reported emissions data is available for Nakakita Yakuhin Co., Ltd. yet.
Nakakita Yakuhin Co., Ltd.'s reported carbon emissions
Nakakita Yakuhin Co., Ltd., a wholesale distributor of drugs and druggists' sundries based in Japan, has not yet publicly disclosed specific figures for its carbon emissions. Consequently, a comprehensive overview of its absolute emissions and performance against reduction targets is unavailable at this time.
However, the company is expected to align with broader industry trends and regulatory expectations concerning climate action within the Japanese pharmaceutical and healthcare supply chain. As is common for companies in this sector, future climate disclosures may focus on Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from the generation of purchased energy), and Scope 3 (all other indirect emissions that occur in a company's value chain).
Companies operating in this industry often explore initiatives to reduce their environmental footprint, which can include improving energy efficiency in their operations, optimising logistics to reduce transportation-related emissions, and engaging with suppliers to promote sustainable practices throughout the value chain. These efforts are crucial for contributing to global climate change mitigation goals.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Nakakita Yakuhin Co., Ltd.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Nakakita Yakuhin Co., Ltd. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Nakakita Yakuhin Co., Ltd.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project